Fosun Pharma Invests RMB 414 Million in Xingyao Kunze's Series B Round to Advance siRNA-Based Hepatitis B Therapies

Note: This article does not constitute any investment advice or recommendations; official/company announcements shall prevail. This article is solely intended for the introduction of healthcare-related pharmaceuticals and does not recommend any treatment regimens (if mentioned), nor does it represent the platform's position.Prior authorization is required for the reproduction of any article.

On May 26, Fosun Pharmaceutical (600196.SH) announced that its controlling subsidiary, Fosun Pharmaceutical Industry, intends to investA total of RMB 414 million was invested in Hepa Thera's Series B financing round.and acquire a portion of the equity interests held by the affiliated companies, Suzhou Fund and Tianjin Fund.

Of which, it intends to contribute RMB 218 million to subscribe for RMB 2.9368 million of the newly increased registered capital of Hepa Thera, and contribute RMB 197 million to acquire a total of RMB 3.0865 million of the existing registered capital held by the Suzhou Fund and the Tianjin Fund. Upon completion of the transaction,Fosun Pharmaceutical Industry will hold a 20.87% equity stake in Hepa Thera.

Founded in May 2021, Hepa Thera is a biopharmaceutical company focused on the development of innovative drugs in the field of liver disease treatment. Leveraging technologies such as RNA interference, antibodies, fusion proteins, and gene editing, Hepa Thera is dedicated to addressing unmet medical needs in liver disease therapy, including hepatitis B, non-alcoholic fatty liver disease, liver fibrosis, liver cirrhosis, and autoimmune liver diseases.